# Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/submitting-documents-using-real-world-data-and-real-world-evidence-to-fda-for-drug-and-biological-products/42c343c9-e823-43a4-a2f7-a2fe152b02aa

> FDA guidance document: Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products. Issue date: September 09, 2022. Get complete insights and analysis.

---

## Details

- Title: Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-09-09
- Last Changed: 2023-03-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-1263">FDA-2019-D-1263</a>

## Related Documents

- [Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/adjusting-for-covariates-in-randomized-clinical-trials-for-drugs-and-biological-products/f58b2adc-b92a-4458-b269-5346d25a8a39)
- [Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability](https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-guidance-for-industry-availability/7511194b-76aa-4116-a433-198583956923)
- [General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-neonatal-studies-for-drugs-and-biological-products-guidance-for-industry/0c57731e-55bc-4962-a619-54444aa22335)